The first US application for a biosimilar, a generic version of Amgen’s Neupogen, was submitted to the FDA in July by Novartis. So far, the FDA has had 59 meetings with companies to discuss 14 biosimilars. Biosimilars are expected to provide a 30% discount to the price of biologics.

Source: BusinessWeek